Review



vegfc 156s 752 vc  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems vegfc 156s 752 vc
    Vegfc 156s 752 Vc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfc 156s 752 vc/product/R&D Systems
    Average 93 stars, based on 41 article reviews
    vegfc 156s 752 vc - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    vegfc 156s 752 vc  (R&D Systems)
    93
    R&D Systems vegfc 156s 752 vc
    Vegfc 156s 752 Vc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfc 156s 752 vc/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    vegfc 156s 752 vc - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    recombinant human vegf-c 100-20cd  (PeproTech)
    90
    PeproTech recombinant human vegf-c 100-20cd
    Recombinant Human Vegf C 100 20cd, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human vegf-c 100-20cd/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant human vegf-c 100-20cd - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant vegf cc156s  (R&D Systems)
    93
    R&D Systems recombinant vegf cc156s
    Recombinant Vegf Cc156s, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant vegf cc156s/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant vegf cc156s - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    vegf c  (R&D Systems)
    93
    R&D Systems vegf c
    Vegf C, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf c/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    vegf c - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    antibody characterization binding nrp2 affinity ligand blocking  (R&D Systems)
    93
    R&D Systems antibody characterization binding nrp2 affinity ligand blocking
    Antibody Characterization Binding Nrp2 Affinity Ligand Blocking, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody characterization binding nrp2 affinity ligand blocking/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    antibody characterization binding nrp2 affinity ligand blocking - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    vegf c156s  (R&D Systems)
    93
    R&D Systems vegf c156s
    ( A ) Schematic for VEGFR3 signaling. Upon ligand binding, VEGFR3 dimerizes, resulting in intracellular autophosphorylation and activation of the downstream genes FOXC2 and DLL4 . V, verubecestat, inhibitor of BACE2. Gene expression levels of ( B ) DLL4 and FOXC2 and ( C ) VEGFR3 after the application of DMSO, 100 nM verubecestat (V), and VEGF-C. ( D and E ) Gene expression levels of DLL4 , FOXC2 , VEGFR3 , BACE1 , and BACE2 after BACE knockdown (siB1/siB2) without or with (+V) subsequent verubecestat application. All dot plots were normalized on the control mean and depict mean and SD alongside the P values calculated by unpaired t tests against the DMSO control ( B and C ) or by 1-way ANOVA ( D and E ), in both cases followed by Bonferroni’s multiple-comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001. P values are only indicated where significance was observed. In B , 1 data point was excluded from the DLL4 <t>expression/VEGF-C156S</t> data set, since it was identified as an outlier via the ROUT method. Data are derived from n = 6 ( B and C ) or n = 4 ( D and E ) biological replicates.
    Vegf C156s, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf c156s/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    vegf c156s - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    verubecestat  (R&D Systems)
    93
    R&D Systems verubecestat
    ( A ) Schematic for VEGFR3 signaling. Upon ligand binding, VEGFR3 dimerizes, resulting in intracellular autophosphorylation and activation of the downstream genes FOXC2 and DLL4 . V, verubecestat, inhibitor of BACE2. Gene expression levels of ( B ) DLL4 and FOXC2 and ( C ) VEGFR3 after the application of DMSO, 100 nM verubecestat (V), and VEGF-C. ( D and E ) Gene expression levels of DLL4 , FOXC2 , VEGFR3 , BACE1 , and BACE2 after BACE knockdown (siB1/siB2) without or with (+V) subsequent verubecestat application. All dot plots were normalized on the control mean and depict mean and SD alongside the P values calculated by unpaired t tests against the DMSO control ( B and C ) or by 1-way ANOVA ( D and E ), in both cases followed by Bonferroni’s multiple-comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001. P values are only indicated where significance was observed. In B , 1 data point was excluded from the DLL4 <t>expression/VEGF-C156S</t> data set, since it was identified as an outlier via the ROUT method. Data are derived from n = 6 ( B and C ) or n = 4 ( D and E ) biological replicates.
    Verubecestat, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/verubecestat/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    verubecestat - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    recombinant human vascular endothelial growth factor c vegf c  (R&D Systems)
    93
    R&D Systems recombinant human vascular endothelial growth factor c vegf c
    ( A ) Schematic for VEGFR3 signaling. Upon ligand binding, VEGFR3 dimerizes, resulting in intracellular autophosphorylation and activation of the downstream genes FOXC2 and DLL4 . V, verubecestat, inhibitor of BACE2. Gene expression levels of ( B ) DLL4 and FOXC2 and ( C ) VEGFR3 after the application of DMSO, 100 nM verubecestat (V), and VEGF-C. ( D and E ) Gene expression levels of DLL4 , FOXC2 , VEGFR3 , BACE1 , and BACE2 after BACE knockdown (siB1/siB2) without or with (+V) subsequent verubecestat application. All dot plots were normalized on the control mean and depict mean and SD alongside the P values calculated by unpaired t tests against the DMSO control ( B and C ) or by 1-way ANOVA ( D and E ), in both cases followed by Bonferroni’s multiple-comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001. P values are only indicated where significance was observed. In B , 1 data point was excluded from the DLL4 <t>expression/VEGF-C156S</t> data set, since it was identified as an outlier via the ROUT method. Data are derived from n = 6 ( B and C ) or n = 4 ( D and E ) biological replicates.
    Recombinant Human Vascular Endothelial Growth Factor C Vegf C, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human vascular endothelial growth factor c vegf c/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant human vascular endothelial growth factor c vegf c - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Schematic for VEGFR3 signaling. Upon ligand binding, VEGFR3 dimerizes, resulting in intracellular autophosphorylation and activation of the downstream genes FOXC2 and DLL4 . V, verubecestat, inhibitor of BACE2. Gene expression levels of ( B ) DLL4 and FOXC2 and ( C ) VEGFR3 after the application of DMSO, 100 nM verubecestat (V), and VEGF-C. ( D and E ) Gene expression levels of DLL4 , FOXC2 , VEGFR3 , BACE1 , and BACE2 after BACE knockdown (siB1/siB2) without or with (+V) subsequent verubecestat application. All dot plots were normalized on the control mean and depict mean and SD alongside the P values calculated by unpaired t tests against the DMSO control ( B and C ) or by 1-way ANOVA ( D and E ), in both cases followed by Bonferroni’s multiple-comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001. P values are only indicated where significance was observed. In B , 1 data point was excluded from the DLL4 expression/VEGF-C156S data set, since it was identified as an outlier via the ROUT method. Data are derived from n = 6 ( B and C ) or n = 4 ( D and E ) biological replicates.

    Journal: The Journal of Clinical Investigation

    Article Title: The Alzheimer’s disease–linked protease BACE2 cleaves VEGFR3 and modulates its signaling

    doi: 10.1172/JCI170550

    Figure Lengend Snippet: ( A ) Schematic for VEGFR3 signaling. Upon ligand binding, VEGFR3 dimerizes, resulting in intracellular autophosphorylation and activation of the downstream genes FOXC2 and DLL4 . V, verubecestat, inhibitor of BACE2. Gene expression levels of ( B ) DLL4 and FOXC2 and ( C ) VEGFR3 after the application of DMSO, 100 nM verubecestat (V), and VEGF-C. ( D and E ) Gene expression levels of DLL4 , FOXC2 , VEGFR3 , BACE1 , and BACE2 after BACE knockdown (siB1/siB2) without or with (+V) subsequent verubecestat application. All dot plots were normalized on the control mean and depict mean and SD alongside the P values calculated by unpaired t tests against the DMSO control ( B and C ) or by 1-way ANOVA ( D and E ), in both cases followed by Bonferroni’s multiple-comparison test. * P < 0.05; ** P < 0.01; **** P < 0.0001. P values are only indicated where significance was observed. In B , 1 data point was excluded from the DLL4 expression/VEGF-C156S data set, since it was identified as an outlier via the ROUT method. Data are derived from n = 6 ( B and C ) or n = 4 ( D and E ) biological replicates.

    Article Snippet: The next morning, medium was replaced with fresh EBM supplemented with DMSO, 100 nM verubecestat, or 1.5 μg/mL VEGF-C156S (752-VC, R&D Systems) and incubated for 100 minutes.

    Techniques: Ligand Binding Assay, Activation Assay, Expressing, Knockdown, Control, Comparison, Derivative Assay